Novartis India (BOM:500672) Beneish M-Score: -2.33 (As of Jun. 30, 2026)


BOM:500672 Novartis India Ltd BOM:500672
59 GF Score
Price ₹1,440.95
GF Value ₹928.24
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Beneish M-Score?

Novartis India BOM:500672 +0.17% 59 Beneish M-Score is -2.33 as of Jun. 30, 2026. GuruFocus rates BOM:500672 with a GF Score™ of 59/100 and a GF Value™ of ₹928.24 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 908 Drug Manufacturers companies, Novartis India ranks worse than 62.44% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.33 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Novartis India's Beneish M-Score or its related term are showing as below:

BOM:500672' s Beneish M-Score Range Over the Past 10 Years
Min: -3.07   Med: -2.3   Max: -0.85
Current: -2.33

During the past 13 years, the highest Beneish M-Score of Novartis India was -0.85. The lowest was -3.07. And the median was -2.30.


Novartis India Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Novartis India's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis India Beneish M-Score Chart

Novartis India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.96 -1.99 -2.54 -2.38 -2.33

Novartis India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.38 0.00 0.00 0.00 -2.33

BOM:500672 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis India Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis India's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Novartis India's Beneish M-Score falls into.


BOM:500672
59GF Score
Novartis India Ltd BOM:500672
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis India Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Novartis India for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7596+0.528 * 0.9785+0.404 * 1.0164+0.892 * 0.9946+0.115 * 0.806
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0+4.679 * 0.047482-0.327 * 0.9774
=-2.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ₹371 Mil.
Revenue was ₹3,543 Mil.
Gross Profit was ₹1,560 Mil.
Total Current Assets was ₹7,683 Mil.
Total Assets was ₹9,783 Mil.
Property, Plant and Equipment(Net PPE) was ₹29 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹20 Mil.
Selling, General, & Admin. Expense(SGA) was ₹0 Mil.
Total Current Liabilities was ₹1,450 Mil.
Long-Term Debt & Capital Lease Obligation was ₹16 Mil.
Net Income was ₹932 Mil.
Gross Profit was ₹0 Mil.
Cash Flow from Operations was ₹467 Mil.
Total Receivables was ₹490 Mil.
Revenue was ₹3,563 Mil.
Gross Profit was ₹1,535 Mil.
Total Current Assets was ₹7,458 Mil.
Total Assets was ₹9,478 Mil.
Property, Plant and Equipment(Net PPE) was ₹45 Mil.
Depreciation, Depletion and Amortization(DDA) was ₹22 Mil.
Selling, General, & Admin. Expense(SGA) was ₹147 Mil.
Total Current Liabilities was ₹1,421 Mil.
Long-Term Debt & Capital Lease Obligation was ₹32 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(370.5 / 3543.3) / (490.4 / 3562.7)
=0.104564 / 0.137648
=0.7596

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1534.5 / 3562.7) / (1559.6 / 3543.3)
=0.430713 / 0.440155
=0.9785

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (7682.5 + 28.8) / 9782.7) / (1 - (7458.2 + 45.4) / 9478.1)
=0.211741 / 0.208322
=1.0164

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3543.3 / 3562.7
=0.9946

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(21.9 / (21.9 + 45.4)) / (19.5 / (19.5 + 28.8))
=0.325409 / 0.403727
=0.806

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(0 / 3543.3) / (147.4 / 3562.7)
=0 / 0.041373
=0

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((15.7 + 1449.7) / 9782.7) / ((32.1 + 1420.5) / 9478.1)
=0.149795 / 0.153259
=0.9774

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(931.8 - 0 - 467.3) / 9782.7
=0.047482

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Novartis India has a M-score of -2.33 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.33 mean?
Novartis India (BOM:500672) has a Beneish M-Score of -2.33 as of Jun. 30, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Novartis India and its competitors. According to the industry distribution chart, Novartis India ranks #567 out of 908 companies in the Drug Manufacturers industry, placing it in the top 62.4%.
Is Novartis India's Beneish M-Score too high?
Novartis India's current Beneish M-Score is -2.33. Based on the distribution chart, Novartis India ranks #567 out of 908 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Novartis India has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Novartis India ranks #567 out of 908 companies for Beneish M-Score. This places Novartis India in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Novartis India and its competitors. Novartis India's current Beneish M-Score is -2.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹928.24, compared to a current price of ₹1,440.95 — trading 55.2% above its estimated fair value. The current Beneish M-Score is -2.33. Novartis India's overall GF Score™ is 59/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Novartis India (BOM:500672), the current Beneish M-Score is -2.33 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis India (BOM:500672) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,440.95 is trading 55.2% above its estimated GF Value™ of ₹928.24. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for BOM:500672:

  • Beneish M-Score: -2.33
  • GF Value™: ₹928.24 vs. price of ₹1,440.95 (55.2% above fair value)
  • GF Score™: 59/100 with 7 warning signs

No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis India Business Description

Other Exchanges NOVARTIND:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
59GF Score

Get the complete analysis for BOM:500672

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,440.95
Price
₹928.24
GF Value